TipRanks
Advertisement
Advertisement
Benitec Biopharma initiated with an Outperform at Wedbush
PremiumThe FlyBenitec Biopharma initiated with an Outperform at Wedbush
2M ago
Guggenheim downgrades Benitec to Neutral, terminates coverage
Premium
The Fly
Guggenheim downgrades Benitec to Neutral, terminates coverage
4M ago
Benitec Biopharma downgraded to Neutral from Buy at Guggenheim
Premium
The Fly
Benitec Biopharma downgraded to Neutral from Buy at Guggenheim
4M ago
Reiterating Buy on Benitec: Promising Early BB-301 Data in OPMD Underpin $32 12‑Month Target
PremiumRatingsReiterating Buy on Benitec: Promising Early BB-301 Data in OPMD Underpin $32 12‑Month Target
7M ago
Benitec Biopharma announces interim Phase 1b/2a study of BB-301
Premium
The Fly
Benitec Biopharma announces interim Phase 1b/2a study of BB-301
7M ago
Benitec Biopharma: Emerging BB-301 Clinical Profile and Upcoming Data Catalyst Support Buy Rating and $32 Target
Premium
Ratings
Benitec Biopharma: Emerging BB-301 Clinical Profile and Upcoming Data Catalyst Support Buy Rating and $32 Target
7M ago
Benitec Biopharma price target lowered to $32 from $35 at H.C. Wainwright
PremiumThe FlyBenitec Biopharma price target lowered to $32 from $35 at H.C. Wainwright
10M ago
Benitec Biopharma: Strong Financial Position and Promising Clinical Developments Justify Buy Rating
Premium
Ratings
Benitec Biopharma: Strong Financial Position and Promising Clinical Developments Justify Buy Rating
11M ago
Citizens JMP healthcare analysts hold an analyst/industry conference
Premium
The Fly
Citizens JMP healthcare analysts hold an analyst/industry conference
11M ago

Trending

Name
Price
Price Change
S&P 500
―
Dow Jones
―
Nasdaq 100
―